Usefulness of dermoscopy to monitor clinical efficacy of imiquimod treatment for lentigo maligna

Archives of Dermatology

Volumn 142, Issue 4, 2006, Pages 530-531

  Micantonio, Tamara ^b   Fargnoli, Maria Concetta ^b   Peris, Ketty ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT;

ACTINIC KERATOSIS; ADULT; CANCER REGRESSION; CASE REPORT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; DRUG EFFICACY; EPILUMINESCENCE MICROSCOPY; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LICHEN PLANUS; MALIGNANT LENTIGO; NOTE; PATIENT MONITORING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PRURITUS; SEBORRHEIC DERMATITIS; SKIN BIOPSY; AGED; CHEEK; DISEASE COURSE; INTRADERMAL DRUG ADMINISTRATION; PATHOLOGY; SKIN TUMOR;

ADMINISTRATION, CUTANEOUS; AGED; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CHEEK; DERMOSCOPY; DISEASE PROGRESSION; FEMALE; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; SKIN NEOPLASMS;

EID: 33646082988     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.4.530-b     Document Type: Note

References (6)

1. Wolf IH, Cerroni L, Kodama K, Kerl H. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol. 2005;141:510-514.
2. Schiffner R, Schiffner-Rohe J, Vogt T, et al. Improvement of early recognition of lentigo maligna using dermatoscopy. J Am Acad Dermatol. 2000;42:25-32.
3. Robinson JK. Use of digital epiluminescence microscopy to help define the edge of lentigo maligna. Arch Dermatol. 2004;140:1095-1100.
4. Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol. 2003;149(S66):66-70.
5. Fleming CJ, Bryden AM, Evans A, Dawe RS, Ibbotson SH. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol. 2004;151:485-488.
6. Chapman MS, Spencer SK, Brennick JB. Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol. 2003;139:943-944.